Veru Inc. (VERU)

1,3300 -0,0400 (-2,92%) Alla chiusura: 04:00PM EDT

Veru Inc.

2916 North Miami Avenue
Suite 1000
Miami, FL 33127
United States
305 509 6897
https://verupharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 189

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Mitchell S. Steiner F.A.C.S., M.D.	Chairman, President & CEO	885,32k	N/D	1961
Dr. Harry Fisch F.A.C.S., M.D.	Vice Chairman & Chief Corporate Officer	N/D	N/D	1959
Ms. Michele Greco	CFO & Chief Administrative Officer	493,7k	N/D	1959
Dr. K. Gary Barnette Ph.D.	Chief Scientific Officer	676,27k	N/D	1968
Mr. Samuel Fisch	Executive Director of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. Michael J. Purvis	Executive VP, General Counsel & Corporate Strategy and Secretary	N/D	N/D	N/D
Mr. Kevin J. Gilbert CPA, J.D.	Executive Vice President of Corporate Development	N/D	N/D	N/D
Mr. Martin Tayler	Executive Vice President of FC2 Global Operations	180,51k	N/D	1969
Mr. Philip R. Greenberg J.D.	Executive VP & Deputy General Counsel	N/D	N/D	N/D
Dr. Domingo Rodriguez M.D.	Executive Vice President of Global Clinical Operations	N/D	N/D	1962

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Governance aziendale

L'ISS Governance QualityScore di Veru Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 8; diritti degli azionisti: 4; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.